RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck s anti-PD-1 therapy, for the adjuvant.
<p>For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer. “We can now tell our patients that pembrolizumab after surgery not only delays recurrences but also helps them live longer,” said the study’s lead investigator <a href="https://www.dana-farber.org/find-a-doctor/toni-choueiri">Toni Choueiri, MD</a>, of <a href="https://www.dana-farber.org/">Dana-Farber Cancer Institute</a>.</p>
KEYNOTE-564 is the first Phase 3 trial to demonstrate superior overall survival with adjuvant therapy compared to placebo in patients with RCC
Late-breaking OS results selected for the official.